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Radboudumc, Nijmegen, The NetherlandsAbstractBecause of the increase in bacterial resistance to commonly used antibacterial drugs, old antibiotics are being ‘revived’ and, once again, are
attracting interest. Many of these old antibiotics were approved long ago, in an era when there was no clear process for development, and
requirements for efﬁcacy to be demonstrated in rigorous clinical trials did not exist. At the time of these approvals, pharmacokinetic and
pharmacodynamic principles were largely unknown, and did not inform the dose-ﬁnding process or recommendations for optimal usage.
Indeed, the task of generating basic vital information for these old antibiotics remains to be performed. In this review, we provide a brief
overview of the most essential data needed for dose justiﬁcation and optimization. An overview of the shortage of data for selected old
antibiotics illustrates the scope of the problem. In order to prevent harming patients with clinical decisions based on inadequate
evidence, a redevelopment procedure for old antibiotics is urgently needed, including a regulatory framework.
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E-mail: jwmouton@gmail.comIntroductionAntibiotics are among the most widely used therapeutic agents
but, despite the increasing understanding of the relationships
between dose, exposure, and outcome, the degree of inade-
quate prescribing remains high [1,2]. This is especially the case
for old antibiotics that have been ‘revived’ because of the rise in
resistance and the resulting need for potentially active agents.
Most of these old antibiotics were registered ﬁve or six decades
ago. Following their original registration, hardly any new in-
formation has been generated, and the original product infor-
mation has not been updated. Indeed, it has become apparent
that original indications for use are sometimes unjustiﬁed, andClinical Microbiology and Infection © 2015 European Society of Cthat many of these antibiotics are used in inadequate doses,
potentially harming patients and promoting the emergence of
resistance. In addition, formulations have changed over time,
resulting in signiﬁcantly different pharmacokinetic (PK) proﬁles
without the corresponding adjustments in the product infor-
mation. In this article, we provide a brief overview of the main
challenges faced in ‘redeveloping’ these old agents from a PK/
pharmacodynamic (PD) perspective for dose justiﬁcation.The early days of antibiotic useDespite Alexander Fleming’s warning in his prescient Nobel
Prize acceptance lecture citing the dangers of excessive use
leading to resistance, shortly thereafter antibiotics were being
aggressively promoted as a cure for almost everything (http://
www.nobelprize.org/nobel_prizes/medicine/laureates/1945/
ﬂeming-speech.html). An example is the advertisement for
‘antibiotic candettes’ for sore throat, which claimed that they
would ‘with double antibiotic action … kill many irritating-Clin Microbiol Infect 2015; 21: 881–885
linical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved
http://dx.doi.org/10.1016/j.cmi.2015.06.007
FIG. 1. Concise diagram of data needed for (re)development of an antibiotic. PD, pharmacodynamic; PK, pharmacokinetic.
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digitalcollections/mma_mm0431/). Antibiotics were freely
available in most parts of the world, registration did not involve
the demonstration of relevant efﬁcacy in comparative trials, and
dosing regimens were not optimized by indication, if at all. In
the USA, evidence for safety of use was required without a
clear deﬁnition of safety. It was only in 1962 that the Kefau-
ver–Harris amendments were signed into law, establishing that
the ‘FDA should be given statutory authority to require proof
of the efﬁcacy, as well as the safety, of all new drugs’ [3]. Food
and Drug Administration (FDA) policies and procedures
resulting from these amendments required that new drugs be
proven to be efﬁcacious via ‘adequate and well-controlled in-
vestigations, including clinical investigations by experts qualiﬁed
by scientiﬁc training and experience, to evaluate the effective-
ness of the drug involved’ [3]. In Europe, prior to 1995, drug
products were approved by national authorities operating with
different requirements, resulting in divergent product infor-
mation across Europe [4]. Since 1995, the European Medicines
Agency has coordinated the evaluation of centrally authorized
products and national referrals to ensure consistency across
European member states. However, this only applies to new
drugs, and not to those with previous approval.Present-day process and requirements for
registration of antibioticsOver time, procedures for registration of antibiotics have
improved signiﬁcantly, with both EU authorities [5–7] and US
authorities [8] (http://www.fda.gov/Drugs/GuidanceCompliance
RegulatoryInformation/Guidances/ucm064980.htm) publishing
numerous guidance documents. Recently, regulatory author-
ities have been adjusting requirements to address the increasing
need for antibiotics that are active against multidrug-resistant
bacteria. Recent guidance documents include recommenda-
tions for dose rationales based on PK/PD relationships, as theseClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectprovide a universal framework for exposure–response re-
lationships, with responses including measures of efﬁcacy,
toxicity, and emergence of resistance. Exposure–response re-
lationships also provide a means to translate experimental and
preclinical exposure–response data to the clinical setting,
including methods and procedures for setting clinical break-
points [9]. Indeed, the process for setting of clinical breakpoints
is extensively described in a recent paper by the European
Committee on Antimicrobial Susceptibility Testing (EUCAST)
[9].
To determine the optimal dose or suitability for a speciﬁc
indication, several essential features of the exposure–response
relationship need to be determined (Fig. 1). In particular,
answering the following three questions is essential:
1. What is the MIC distribution of the microorganisms of
interest?
2. What are the exposures (PK proﬁles) for various doses and
patient populations?
3. What are the exposure–response relationship and PD
target?
The answer to each of these questions provides the basis for
adequate dosing that can subsequently be explored and vali-
dated in clinical trials. Answering the ﬁrst two questions re-
quires descriptive studies to characterize parameter estimates,
whereas answering the third question involves modelling the
PK/PD relationship. Most often the PD properties are esti-
mated from other species, such as rodents or dogs [10]. Then,
after PK data are available from phase 1 studies, a ﬁrst esti-
mated dose–exposure relationship in humans can be estab-
lished as basis for relating dose and exposure to a selected
effect. Further evidence of efﬁcacy and the exposure–response
relationship is subsequently accumulated during phase 2 and 3
studies. All of these data feed into an evidence-based selection
of a dosing regimen that is stratiﬁed by indication and patient
population, such as patients with enhanced renal clearance. Theious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 881–885
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deserves special consideration, and is described in a companion
article in this issue [11].What are the gaps in the evidence for old
antibiotics?It follows from the two previous sections that there is a sig-
niﬁcant knowledge gap for many old antibiotics. The optimal
dosage of old, especially recently revived, antibiotics is often
unknown. This is underscored by the observation that the
dosing range of older antibiotics entails a vast spectrum of
doses and dose frequencies, whereas usually only one, or at
most two, regimens exist for the newer antibiotics. Addition-
ally, for older antibiotics, the clinical indications described in the
product information are usually broad, and extend far beyond
the recognized appropriate use of antibiotics. Both of these
issues have signiﬁcant consequences for patient care, resulting
in overdosing and underdosing because of inadequate dosing
regimens, as well as inadequate treatment because of unsuitable
indications.
Regarding the minimal information required for (re)devel-
opment (Fig. 1), many of the old antibiotics lack signiﬁcant as-
pects of this vital information. Table 1 provides aTABLE 1. Comprehensive overview of revived antibiotics and examp
indication of the pharmacokinetic (PK)/pharmacodynamic (PD)
1 [ poor (£3 studies/setting); 2 [ fair (at least 4 studies/setting
population PK analysesa)
Antibiotic
PK proﬁling in
volunteers
PK pro
in patie
Revived antibiotics
Chloramphenicol and thiamphenicol 3 3
Colistin 1 3
Co-trimoxazole 2 1
Doxycyclin 3 3
Fosfomycin IV 2 2
Fusidic acid 3 3
Methenamine 1 0
Minocyclin 3 3
Nitrofurantoin 1 1
Nitroxoline 1 1
(Piv)mecillinam 2 2
Polymyxin B 0 3
Pristinamycin 1 1
Quinupristin–dalfopristin 1 0
Rifampicin 3 3
Spectinomycin 1 0
Teicoplanin 3 3
Temocillin 1 2
Trimethoprim 2 1
Examples of ‘old’ antibiotics in current use
Azithromycin 3 3
Ceftazidime 3 3
Erythromycin 3 3
Flucloxacillin 3 1
Tigecycline 2 3
Tobramycin 3 3
aNote a different categorization for the PD target derived from clinical studies; only categor
Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiologycomprehensive list of old and revived antimicrobials and an
indication of signiﬁcant knowledge gaps in the areas of PK
proﬁling in volunteers and patients, as well as PD targets
derived from preclinical and clinical studies. Data were
retrieved from Kucers’ 6th edition [12], supplemented with a
search in PubMed from 2010 to 2015 for each compound listed.
The amount of information for each column was subsequently
judged and categorized from 0 (no information found) to 3
(information available according to current standards for new
drugs). Although by no means fully complete, the list clearly
indicates that, for many antibiotics, signiﬁcant work needs to be
performed.
Non-clinical PK/PD studies
Non-clinical PK/PD studies evaluating exposure–response re-
lationships, and therefore a PD target, are lacking for many
older drugs. Colistin is the most notable example. Soon after it
became available in the early 1950s, the use of colistin was
discontinued, because of signiﬁcant side effects and the advent
of more effective agents. With its recent revival, however,
colistin is now being extensively used again in some parts of the
world. For some other antibiotics, there is the beneﬁt of known
class effects, which have usually been studied thoroughly since
the 1990s (examples are included in Table 1). Typical examples
are ceftazidime and the class of cephalosporins with well-
established exposure–response relationships [13].les of old antibiotics that have been continuously used, with an
information presently available (0 [ no information found;
); 3 [ following current standards for new drugs, including
ﬁling
nts
PD target derived from
preclinical studies
PD target derived
from clinical studiesa
0 0
2 0
0 0
0 0
1 0
0 0
0 0
1 0
0 0
0 0
0 0
2 0
0 0
0 0
1 3
0 0
2 3
0 0
0 0
2 3
3 3
1 0
0 0
1 3
3 3
ized as 0 (not available) or 3 (at least 1 available).
and Infectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 881–885
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Exposure–response relationships in patients have been
increasingly studied over the last two decades [14]. Despite
more relevant information being available for some old antibi-
otics, the recently revived agents notably lack the basic infor-
mation needed to support appropriate dosing recommendations
to optimize efﬁcacy, to minimize side effects, and to address the
emergence of resistance. Again, colistin is a good example [15],
but even for drugs that are used commonly, such as nitro-
furantoin or doxycycline, data are almost non-existent [16].
PK studies
For many of the older antibiotics, substantial PK data are
available, much of it from volunteers. However, most of these
data were analysed with methods developed 50 years ago, when
population PK programmes did not exist, and covariate analyses
were not yet performed. Even today, PK data for speciﬁc pa-
tient groups, such as the elderly or patients with enhanced or
reduced clearance, are often unavailable [11].
Wild-type MIC distributions
Wild-type MIC distributions represent the activity of the anti-
microbial against speciﬁc bacterial species [17,18]. Because of
inherent biological variation and testing methods, the distribu-
tion usually extends over four to ﬁve two-fold dilutions. Given
this variation, it is impossible to accurately and reproducibly
measure an MIC within one dilution. Therefore, when clinical
breakpoints are established on the basis of PD targets, the
exposure—and therefore dosing—required to reach the
target should take into account the epidemiological cut-off
value as a minimum MIC to cover. Wild-type MIC distribu-
tions of old antibiotics are, by and large, well described. Most of
these are available to the public on the website of the EUCAST
(www.EUCAST.org).Why are there gaps in evidence for old
antibiotics?There are two main reasons for the knowledge and evidence
gaps. First, although the regulatory requirements for new anti-
biotics have grown more stringent over time, procedures that
require an update of the product information (Summary of
Product Characteristics) for old antibiotics are either non-
existent or insufﬁcient. Thus, the greatly improved understand-
ing of how antibiotics work and are optimally used is not
consistently translated to the ofﬁcial Summary of Product Char-
acteristics of an older agent, and, in general, is not included in
guidelines. This is a critical problem for revived antibiotics, as the
considerable knowledge gaps pose signiﬁcant risks of potentialClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectharm to patients. Thus, we need to produce a solid strategy to
‘redevelop’ these old drugs in academic settings, with modern
standards that integrate new knowledge into regulatory frame-
works and translate this knowledge from research bench to
bedside. Second, there is no incentive for companies to continue
developing an antimicrobial after approval beyond commercial
interests and time frames, even if there is a clear medical need.What can be done going forwards?There is a clear need for redevelopment of old antibiotics,
especially recently revived ones, via a collaborative and struc-
tured process that should resemble the development of new
antibiotics. Although academia and clinicians are performing
studies in an uncoordinated way, they are currently stepping in
and ﬁlling some gaps. On the other hand, there are several
examples of coordinated strategies in initiatives from the EU in
the European 7th Framework programme [19], the European
Innovative Medicines Initiative (IMI) project (http://www.imi.
europa.eu/content/nd4bb), and the National Institutes of
Health [20], which have each contributed funds for the rede-
velopment of older antibiotics. Part of the IMI programme in-
volves the re-analysis of old PK data made available by
participating companies with modern software, to gain more
insights into PK proﬁles. The experience gained with these
publicly funded projects will help to establish clear guidelines
for redevelopment processes outside the corporate world.
In conclusion, strategies are urgently needed that stimulate and
fund coordinated redevelopment processes [21], in particular
regarding exposure–response relationships, to justify adequate
dosing regimens and re-evaluate indications. New knowledge
needs to be integrated into regulatory frameworks, and updated
treatment recommendations introduced into clinical practice to
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